Houston hospital performs first fully robotic heart transplant in the U.S.

robotic surgery

Dr. Kenneth Liao and a team at Baylor St. Luke’s Medical Center used a surgical robot to implant a new heart in a 45-year-old male patient. Photo courtesy Baylor College of Medicine.

A team at Baylor St. Luke’s Medical Center, led by Dr. Kenneth Liao, successfully performed the first fully robotic heart transplant in the United States earlier this year, the Houston hospital recently shared.

Liao, a professor and chief of cardiothoracic transplantation and circulatory support at Baylor College of Medicine and chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke’s Medical Center, used a surgical robot to implant a new heart in a 45-year-old male patient through preperitoneal space in the abdomen by making small incisions.

The robotic technology allowed the medical team to avoid opening the chest and breaking the breast bone, which reduces the risk of infection, blood transfusions and excessive bleeding. It also leads to an easier recovery, according to Liao.

"Opening the chest and spreading the breastbone can affect wound healing and delay rehabilitation and prolong the patient's recovery, especially in heart transplant patients who take immunosuppressants," Liao said in a news release. "With the robotic approach, we preserve the integrity of the chest wall, which reduces the risk of infection and helps with early mobility, respiratory function and overall recovery."

The patient received the heart transplant in March, after spending about four months in the hospital due to advanced heart failure. According to Baylor, he was discharged home after recovering from the surgery in the hospital for a month without complications.

"This transplant shows what is possible when innovation and surgical experience come together to improve patient care," Liao added in the release. "Our goal is to offer patients the safest, most effective and least invasive procedures, and robotic technology allows us to do that in extraordinary ways."

From Your Site Articles
BiVACOR and The Texas Heart Institute have celebrated a major milestone in the future of heart health. Photo courtesy of BiVACOR

Houston medical device startup implants artificial heart in first human patient

big win

Heart health tech company BiVACOR and The Texas Heart Institute announced that they successfully implanted the company's first Total Artificial Heart in a human at Baylor St. Luke’s Medical Center in the TMC.

The milestone is part of an FDA-approved early feasibility study that will test the safety and performance of the TAH device, which is based on a magnetically levitated rotor that takes over functions of a failing heart while a patient is awaiting a heart transplant, according to a statement from the organizations.

The "bridge-to-transplant" device could support an active adult male, as well as many women and children suffering from severe biventricular heart failure or univentricular heart failure.

"With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant,” Dr. Joseph Rogers, president and CEO of THI and national principal investigator on the research, says in a statement. “We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.”

BiVACOR received approval from the FDA for the early feasibility study in late 2023 and has four other patients enrolled in the study. At the time the study was approved, 10 hospitals were enrolled as possible sites.

“I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute ... our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial,” Daniel Timms, PhD, founder and CTO of BiVACOR, adds.

About 100,000 patients suffering from severe heart failure could benefit from BiVACOR’s artificial heart, the company says. Globally, only about 6,000 heart transplants are performed each year, while 26 million people worldwide are affected by heart failure.

BiVACOR was founded in 2008 and maintains its headquarters in Houston, along with offices in Huntington Beach, California, and Brisbane, Australia.

To date, the company has raised nearly $50.8 million, according to CB Insights. The company raised $18 million in 2023, and $22 million in 2021.

Earlier this year, BiVACOR named a new CEO in Jim Dillon, a longtime executive in the medical device sector.

Last summer, Rogers joined the Houston Innovators Podcast to share his excitement with THI's innovations.


Thomas Vassiliades, CEO of BiVACOR, joins the Houston Innovators Podcast. Photo courtesy of BiVACOR

How this Houston-headquartered company is innovating the future of heart replacement

HOUSTON INNOVATORS PODCAST EPISODE 183

Heart disease is one of the most common causes of death in the United States — one in five deaths, according to the CDC. But there's not a long-term solutions for patients — even for those lucky enough to have a successful heart transplant. But a Houston-headquartered medical device company is working on one.

BiVACOR has created a technology that, theoretically, could completely replace a patient's heart and last them the rest of their lives.

"The design is critical," says Thomas Vassiliades, CEO of BiVACOR, on the Houston Innovators Podcast. He joined the organization last year after spending 20 years of a heart surgeon, then transitioning to medical device development over a decade ago.

Vassiliades explains the industry's challenges on the show, saying that there's no comprehensive, lasting replacement to the human heart on the market. While some treatments — like transplants and medical devices that partially replace the heart's capabilities — exist, nothing that completely replaces the heart lasts longer than 10 to 12 years.

"The BiVACOR system is based on magnetic levitation," Vassiliades says about the technology. "Our pump is just one moving impeller that sits in the middle of the housing where the blood is. Imagine an artificial heart — the container that has your blood — and the device spinning in the inside — basically a wheel spinning your blood to the rest of your body.

"The device is suspended by magnets — it's not touching anything," he continues. "So, theoretically, the device has no wear and can last as long as the patient can possibly live. That's new to the field."

Daniel Timms, BiVACOR's founder and CTO, knew there had to be a better, more permanent solution and has been working on the technology since he was a postdoctoral student at Queensland University of Technology in Australia. His work took him to Houston's Texas Heart Institute, the "center of the universe when it comes to blood pumps," says Vassiliades.

The company recently raised $18 million in funding to support its growing team and continued growth. BiVACOR is a Class 3 medical device — the most rigorously regulated type of device, so the funding raised will support the company as it continues to meet the FDA's requirements and proceeds into implantation and clinical trials.

While headquartered in Houston and has close ties to THI, most of BiVACOR's team works out of Huntington Beach, California, just 30 minutes away from its manufacturing partner — something that has been critical for the design phase. Other employees work in Europe and Australia, which has resulted in government grant funding. Each market the company works in has a strategic purpose — and Houston's role is testing.

"We're going to be training all our clinical sites in Houston, and we're going to continue to do ongoing testing," he says. "We're very comfortable with the design of the device, ... but there's always more. And we have a long-term plan to iterate on the device to make it even better."

Vassiliades shares more of the challenges he's facing as he commercializes BiVACOR's technology on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Tech giant Apple doubles down on Houston with new production facility

coming soon

Tech giant Apple announced that it will double the size of its Houston manufacturing footprint as it brings production of its Mac mini to the U.S. for the first time.

The company plans to begin production of its compact desktop computer at a new factory at Apple’s Houston manufacturing site later this year. The move is expected to create thousands of jobs in the Houston area, according to Apple.

Last year, the Cupertino, California-based company announced it would open a 250,000-square-foot factory to produce servers for its data centers in the Houston area. The facility was originally slated to open in 2026, but Apple reports it began production ahead of schedule in 2025.

The addition of the Mac mini operations at the site will bring the footprint to about 500,000 square feet, the Houston Chronicle reports. The New York Times previously reported that Taiwanese electronics manufacturer Foxconn would be involved in the Houston factory.

Apple also announced plans to open a 20,000-square-foot Advanced Manufacturing Center in Houston later this year. The project is currently under construction and will "provide hands-on training in advanced manufacturing techniques to students, supplier employees, and American businesses of all sizes," according to the announcement. Apple opened a similar Apple Manufacturing Academy in Detroit last year.

Apple doubles down on Houston with new production facility, training center Photo courtesy Apple.

“Apple is deeply committed to the future of American manufacturing, and we’re proud to significantly expand our footprint in Houston with the production of Mac mini starting later this year,” Tim Cook, Apple’s CEO, said in the news release. “We began shipping advanced AI servers from Houston ahead of schedule, and we’re excited to accelerate that work even further.”

Apple's Houston expansion is part of a $600 billion commitment the company made to the U.S. in 2025.

Houston energy trailblazer Fervo taps into hottest reservoir to date

Heating Up

Things are heating up at Houston-based geothermal power company Fervo Energy.

Fervo recently drilled its hottest well so far at a new geothermal site in western Utah. Fewer than 11 days of drilling more than 11,000 feet deep at Project Blanford showed temperatures above 555 degrees Fahrenheit, which exceeds requirements for commercial viability. Fervo used proprietary AI-driven analytics for the test.

Hotter geothermal reservoirs produce more energy and improve what’s known as energy conversion efficiency, which is the ratio of useful energy output to total energy input.

“Fervo’s exploration strategy has always been underpinned by the seamless integration of cutting-edge data acquisition and advanced analytics,” Jack Norbeck, Fervo’s co-founder and chief technology officer, said in a news release. “This latest ultra-high temperature discovery highlights our team’s ability to detect and develop EGS sweet spots using AI-enhanced geophysical techniques.”

Fervo says an independent review confirms the site’s multigigawatt potential.

The company has increasingly tapped into hotter and hotter geothermal reservoirs, going from 365 degrees at Project Red to 400 degrees at Cape Station and now more than 555 degrees at Blanford.

The new site expands Fervo’s geologic footprint. The Blanford reservoir consists of sedimentary formations such as sandstones, claystones and carbonates, which can be drilled more easily and cost-effectively than more commonly targeted granite formations.

Fervo ranks among the top-funded startups in the Houston area. Since its founding in 2017, the company has raised about $1.5 billion. In January, Fervo filed for an IPO that would value the company at $2 billion to $3 billion, according to

Axios Pro.

---

This article originally appeared on EnergyCapitalHTX.com.

11 Houston researchers named to Rice innovation cohort

top of class

The Liu Idea Lab for Innovation and Entrepreneurship (Lilie) has named 11 students and researchers with breakthrough ideas to its 2026 Rice Innovation Fellows cohort.

The program, first launched in 2022, aims to support Rice Ph.D. students and postdocs in turning their research into real-world ventures. Participants receive $10,000 in translational research funding, co-working space and personalized mentorship.

The eleven 2026 Innovation Fellows are:

Ehsan Aalaei, Bioengineering, Ph.D. 2027

Professor Michael King Laboratory

Aalaei is developing new therapies to prevent the spread of cancer.

Matt Lee, Bioengineering, Ph.D. 2027

Professor Caleb Bashor Laboratory

Lee’s work uses AI to design the genetic instructions for more effective therapies.

Thomas Howlett, Bioengineering, Postdoctoral 2028

Professor Kelsey Swingle Laboratory

Howlett is developing a self-administered, nonhormonal treatment for heavy menstrual bleeding.

Jonathan Montes, Bioengineering, Ph.D. 2025

Professor Jessica Butts Laboratory

Montes and his team are developing a fast-acting, long-lasting nasal spray to relieve chronic and acute anxiety.

Siliang Li, BioSciences, Postdoctoral 2025

Professor Caroline Ajo-Franklin Laboratory

Li is developing noninvasive devices that can quickly monitor gut health signals.

Gina Pizzo, Statistics, Lecturer

Pizzo’s research uses data modeling to forecast crop performance and soil health.

Alex Sadamune, Bioengineering, Ph.D. 2027

Professor Chong Xie Laboratory

Sadamune is working to scale the production of high-precision neural implants.

Jaeho Shin, Chemistry, Postdoctoral 2027

Professor James M. Tour Laboratory

Shin is developing next-generation semiconductor and memory technologies to advance computing and AI.

Will Schmid, Electrical and Computer Engineering, Postdoctoral 2025

Professor Alessandro Alabastri Laboratory

Schmid is developing scalable technologies to recover critical minerals from high-salinity resources.

Khadija Zanna, Electrical and Computer Engineering, Ph.D. 2026

Professor Akane Sano Laboratory

Zanna is building machine learning tools to help companies deploy advanced AI in compliance with complex global regulations.

Ava Zoba, Materials Science and Nano Engineering, Ph.D. 2029

Professor Christina Tringides Laboratory

Zoba is designing implantable devices to improve the monitoring of brain function following tumor-removal surgery.

According to Rice, its Innovation Fellows have gone on to raise over $30 million and join top programs, including The Activate Fellowship, Chain Reaction Innovations Fellowship, the Texas Medical Center’s Cancer Therapeutics Accelerator and the Rice Biotech Launch Pad. Past participants include ventures like Helix Earth Technologies and HEXASpec.

“These fellows aren’t just advancing science — they’re building the future of industry here at Rice,” Kyle Judah, Lilie’s executive director, said in a news release. “Alongside their faculty members, they’re stepping into the uncertainty of turning research into real-world solutions. That commitment is rare, and it’s exactly why Lilie and Rice are proud to stand shoulder-to-shoulder with them and nurture their ambition to take on civilization-scale problems that truly matter.”

View All Listings